Annual Total Long Term Liabilities
$713.03 M
-$470.00 M-39.73%
31 December 2023
Summary:
BioMarin Pharmaceutical annual total long term liabilities is currently $713.03 million, with the most recent change of -$470.00 million (-39.73%) on 31 December 2023. During the last 3 years, it has fallen by -$536.44 million (-42.93%). BMRN annual total long term liabilities is now -42.93% below its all-time high of $1.25 billion, reached on 31 December 2020.BMRN Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$722.14 M
+$8.66 M+1.21%
30 September 2024
Summary:
BioMarin Pharmaceutical quarterly total long term liabilities is currently $722.14 million, with the most recent change of +$8.66 million (+1.21%) on 30 September 2024. Over the past year, it has increased by +$24.10 million (+3.45%). BMRN quarterly long term liabilities is now -46.49% below its all-time high of $1.35 billion, reached on 30 September 2017.BMRN Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMRN Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -39.7% | +3.5% |
| 3 y3 years | -42.9% | -39.6% |
| 5 y5 years | -23.8% | -27.1% |
BMRN Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -42.9% | at low | -39.6% | +3.5% |
| 5 y | 5 years | -42.9% | +12.3% | -42.3% | +13.7% |
| alltime | all time | -42.9% | >+9999.0% | -46.5% | >+9999.0% |
BioMarin Pharmaceutical Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $722.14 M(+1.2%) |
| June 2024 | - | $713.49 M(+0.4%) |
| Mar 2024 | - | $710.96 M(-0.3%) |
| Dec 2023 | $713.03 M(-39.7%) | $713.03 M(+2.1%) |
| Sept 2023 | - | $698.04 M(-41.0%) |
| June 2023 | - | $1.18 B(+0.6%) |
| Mar 2023 | - | $1.18 B(-0.6%) |
| Dec 2022 | $1.18 B(-0.8%) | $1.18 B(+0.7%) |
| Sept 2022 | - | $1.17 B(-0.2%) |
| June 2022 | - | $1.18 B(-0.4%) |
| Mar 2022 | - | $1.18 B(-1.0%) |
| Dec 2021 | $1.19 B(-4.6%) | $1.19 B(-0.3%) |
| Sept 2021 | - | $1.20 B(-1.4%) |
| June 2021 | - | $1.21 B(+0.0%) |
| Mar 2021 | - | $1.21 B(-2.9%) |
| Dec 2020 | $1.25 B(+96.7%) | $1.25 B(-0.0%) |
| Sept 2020 | - | $1.25 B(-0.2%) |
| June 2020 | - | $1.25 B(+89.0%) |
| Mar 2020 | - | $662.41 M(+4.3%) |
| Dec 2019 | $635.15 M(-32.1%) | $635.15 M(-35.8%) |
| Sept 2019 | - | $989.98 M(-0.3%) |
| June 2019 | - | $993.00 M(-0.5%) |
| Mar 2019 | - | $997.78 M(+6.6%) |
| Dec 2018 | $935.95 M(-7.1%) | $935.95 M(-0.6%) |
| Sept 2018 | - | $941.65 M(+0.8%) |
| June 2018 | - | $934.63 M(-8.0%) |
| Mar 2018 | - | $1.02 B(+0.8%) |
| Dec 2017 | $1.01 B(+23.2%) | $1.01 B(-25.3%) |
| Sept 2017 | - | $1.35 B(+58.8%) |
| June 2017 | - | $850.08 M(+2.5%) |
| Mar 2017 | - | $829.31 M(+1.4%) |
| Dec 2016 | $818.11 M(-7.4%) | $818.11 M(-0.1%) |
| Sept 2016 | - | $819.10 M(+1.7%) |
| June 2016 | - | $805.15 M(-18.6%) |
| Mar 2016 | - | $988.75 M(+12.0%) |
| Dec 2015 | $883.06 M(+24.1%) | $883.06 M(-6.2%) |
| Sept 2015 | - | $941.72 M(-0.2%) |
| June 2015 | - | $944.03 M(+1.8%) |
| Mar 2015 | - | $927.73 M(+30.3%) |
| Dec 2014 | $711.75 M(-1.1%) | $711.75 M(-1.9%) |
| Sept 2014 | - | $725.44 M(+1.2%) |
| June 2014 | - | $717.00 M(-1.0%) |
| Mar 2014 | - | $724.57 M(+0.7%) |
| Dec 2013 | $719.75 M(+88.3%) | $719.75 M(+308.0%) |
| Sept 2013 | - | $176.41 M(-12.2%) |
| June 2013 | - | $201.02 M(-1.5%) |
| Mar 2013 | - | $204.13 M(-46.6%) |
| Dec 2012 | $382.15 M(-12.9%) | $382.15 M(-8.4%) |
| Sept 2012 | - | $417.25 M(+1.2%) |
| June 2012 | - | $412.10 M(+1.7%) |
| Mar 2012 | - | $405.32 M(-7.6%) |
| Dec 2011 | $438.54 M | $438.54 M(+0.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2011 | - | $437.28 M(-6.2%) |
| June 2011 | - | $466.05 M(-0.3%) |
| Mar 2011 | - | $467.32 M(+1.3%) |
| Dec 2010 | $461.52 M(-10.7%) | $461.52 M(-18.6%) |
| Sept 2010 | - | $566.77 M(+5.2%) |
| June 2010 | - | $538.62 M(-0.7%) |
| Mar 2010 | - | $542.27 M(+4.9%) |
| Dec 2009 | $516.82 M(+3.4%) | $516.82 M(+3.1%) |
| Sept 2009 | - | $501.43 M(+0.1%) |
| June 2009 | - | $500.97 M(+0.2%) |
| Mar 2009 | - | $500.03 M(+0.0%) |
| Dec 2008 | $499.94 M(-11.7%) | $499.94 M(-0.1%) |
| Sept 2008 | - | $500.40 M(-11.4%) |
| June 2008 | - | $565.11 M(-0.0%) |
| Mar 2008 | - | $565.23 M(-0.1%) |
| Dec 2007 | $566.01 M(+88.9%) | $566.01 M(-0.3%) |
| Sept 2007 | - | $567.45 M(-0.4%) |
| June 2007 | - | $569.49 M(+131.3%) |
| Mar 2007 | - | $246.22 M(-17.8%) |
| Dec 2006 | $299.59 M(+28.9%) | $299.59 M(-0.7%) |
| Sept 2006 | - | $301.73 M(-21.0%) |
| June 2006 | - | $381.82 M(-0.9%) |
| Mar 2006 | - | $385.34 M(+65.8%) |
| Dec 2005 | $232.40 M(+0.7%) | $232.40 M(+1.0%) |
| Sept 2005 | - | $230.00 M(-1.7%) |
| June 2005 | - | $233.99 M(+6.1%) |
| Mar 2005 | - | $220.47 M(-4.5%) |
| Dec 2004 | $230.89 M(+83.7%) | $230.89 M(+3.8%) |
| Sept 2004 | - | $222.35 M(-0.3%) |
| June 2004 | - | $222.96 M(+77.8%) |
| Mar 2004 | - | $125.36 M(-0.2%) |
| Dec 2003 | $125.67 M(+2304.7%) | $125.67 M(-0.4%) |
| Sept 2003 | - | $126.24 M(-1.9%) |
| June 2003 | - | $128.70 M(+2762.5%) |
| Mar 2003 | - | $4.50 M(-14.0%) |
| Dec 2002 | $5.23 M(+31.9%) | $5.23 M(+79.5%) |
| Sept 2002 | - | $2.91 M(-15.9%) |
| June 2002 | - | $3.46 M(-1.1%) |
| Mar 2002 | - | $3.50 M(-11.6%) |
| Dec 2001 | $3.96 M(+6973.2%) | $3.96 M(+2613.0%) |
| Sept 2001 | - | $146.00 K(-26.3%) |
| June 2001 | - | $198.00 K(+321.3%) |
| Mar 2001 | - | $47.00 K(-16.1%) |
| Dec 2000 | $56.00 K(-34.1%) | $56.00 K(-11.1%) |
| Sept 2000 | - | $63.00 K(-7.4%) |
| June 2000 | - | $68.00 K(-11.7%) |
| Mar 2000 | - | $77.00 K(-9.4%) |
| Dec 1999 | $85.00 K(-22.7%) | $85.00 K(-15.0%) |
| Sept 1999 | - | $100.00 K(-99.6%) |
| June 1999 | - | $26.10 M(>+9900.0%) |
| Mar 1999 | - | $100.00 K |
| Dec 1998 | $110.00 K | - |
FAQ
- What is BioMarin Pharmaceutical annual total long term liabilities?
- What is the all time high annual total long term liabilities for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual total long term liabilities year-on-year change?
- What is BioMarin Pharmaceutical quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly long term liabilities year-on-year change?
What is BioMarin Pharmaceutical annual total long term liabilities?
The current annual total long term liabilities of BMRN is $713.03 M
What is the all time high annual total long term liabilities for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual total long term liabilities is $1.25 B
What is BioMarin Pharmaceutical annual total long term liabilities year-on-year change?
Over the past year, BMRN annual total long term liabilities has changed by -$470.00 M (-39.73%)
What is BioMarin Pharmaceutical quarterly total long term liabilities?
The current quarterly long term liabilities of BMRN is $722.14 M
What is the all time high quarterly long term liabilities for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly total long term liabilities is $1.35 B
What is BioMarin Pharmaceutical quarterly long term liabilities year-on-year change?
Over the past year, BMRN quarterly total long term liabilities has changed by +$24.10 M (+3.45%)